aziridonin 44

a natural product of the medicinal herb Rabdosia rubescens

Also Known As:

(2R,3'S,3a'R,3a1'R,6a'R,7'S,11'S,11a'S)-1-acryloyl-7',11'-dihydroxy-5',5',8',8'-tetramethyldecahydro-2'H-spiro(aziridine-2,15'-(6a,11a)(epoxymethano)(3,3a1)ethanophenanthro(1,10-de)(1,3)dioxin)-14'-one; YD0514

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azirines
    - Aziridines: 14
      - aziridonin 44: 2

Experts

1.	Ding, Ye: 2 articles (12/2018 - 01/2018)
2.	Li, Dengfeng: 2 articles (12/2018 - 01/2018)
3.	Shen, Qiang: 2 articles (12/2018 - 01/2018)
4.	Zhou, Jia: 2 articles (12/2018 - 01/2018)
5.	Chen, Haiying: 1 article (12/2018)
6.	Ding, Chunyong: 1 article (12/2018)
7.	Liu, Zhiqing: 1 article (12/2018)
8.	Wang, Pingyuan: 1 article (12/2018)
9.	White, Mark A: 1 article (12/2018)
10.	Wold, Eric A: 1 article (12/2018)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/2018 - "In this study, we found that YD0514 significantly inhibited proliferation, motility, and adhesion of metastatic breast cancer cell lines MDA-MB-231, GI101, GILM2, and GILM3. " 01/01/2018 - "Lastly, we showed that YD0514's anti-metastatic effect on highly aggressive breast cancer is mediated via regulating the NRF-2/RHOA/ROCK signaling pathway. " 01/01/2018 - "Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis." 01/01/2018 - "Importantly, YD0514 suppressed the growth of metastatic breast cancer xenograft tumors and significantly inhibited lung metastasis in vivo. "
2.	Triple Negative Breast Neoplasms 12/01/2018 - "Importantly, aziridonin 44 (YD0514), with a more-druglike irreversible covalent warhead, has been identified to significantly induce apoptosis and inhibit colony formation against triple-negative breast cancer with enhanced antitumor effects in vitro and in vivo while displaying lower toxicity to normal human mammary epithelial cells in comparison to oridonin."
3.	Neoplasms (Cancer) 01/01/2018 - "Importantly, YD0514 suppressed the growth of metastatic breast cancer xenograft tumors and significantly inhibited lung metastasis in vivo. " 01/01/2018 - "These results demonstrate that YD0514, the first active analog based on an oridonin D-ring modification, has the potential to be developed as an anti-metastasis therapy for patients with metastatic cancers."
4.	Neoplasm Metastasis (Metastasis) 01/01/2018 - "Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis." 01/01/2018 - "Importantly, YD0514 suppressed the growth of metastatic breast cancer xenograft tumors and significantly inhibited lung metastasis in vivo. " 01/01/2018 - "These results demonstrate that YD0514, the first active analog based on an oridonin D-ring modification, has the potential to be developed as an anti-metastasis therapy for patients with metastatic cancers."

Related Drugs and Biologics

1.	oridonin
2.	aziridonin 44

Related Therapies and Procedures

1.	Therapeutics